CoChat

Breast Cancer Management: Quality-of-Life and Cost Considerations

Radice, Davide, Redaelli, Alberto · 2003 · PharmacoEconomics

The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.

Abstract

The purpose of this article was to provide a literature-based extensive overview of the quality-of-life and cost issues posed by the management of breast cancer. Incidence and mortality rates vary widely in different countries. Breast cancer accounts approximately for one-fifth of all deaths in women aged 40-50 years. The 1994-1998 incidence rate in the US population was on average 114.3 per 100 000 women. Treatment options include surgery, radiotherapy and drug therapy (cytotoxic and endocrine drugs). All treatment options affect patients' health-related quality of life (HR-QOL) in various ways. The use of cytotoxic agents has a particularly large HR-QOL impact. HR-QOL questionnaires are complex tools, not routinely used in breast cancer trials.Worldwide, around 10 million individuals develop cancer each year; this figure is expected to increase to 15 million in 2020. For all cancers, the total economic burden of this disease worldwide was projected by the authors to be in the range of $US 300-400 billion in 2001 (about $US 100-140 billion as direct costs and the remainder as indirect costs [morbidity and mortality]). According to the National Institute of Health (NIH), the total cost of cancer was estimated at $US 156.7 billion in 2001 in US ($US 56.4 billion as direct costs, $US 15.6 as indirect morbidity costs, and $US 84.7 billion as indirect mortality costs). Based on limited information, in the US, breast cancer can be projected to account for about one-fifth/one-fourt…

Overview

Integrity signals

Registry

Crossref · 10.2165/00019053-200321060-00003

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Research works printed but not linked: 12

  1. 16, eb, 1325, 1
  2. Fisher, 1989, N Engl J Med, 320, 478
  3. Radice, 2000, Qual Life Res, 9, 1065
  4. Selby, 1984, Rev Endocr Related Cancer, 14, 245
  5. Mor, 1994, J Natl Cancer Inst Monogr, 16, 191
  6. Edlund, 1989, Oncol Nurs Forum, 16, 691
  7. Schagen, 2000, O-N-E, 1, 48
  8. Brown, 1994, NCI, 13, 255
  9. Thom, 1996, In Vivo, 10, 255
  10. Brown, 1990, NCI, 5, 69
  11. Shapiro, 1982, J Natl Cancer Inst, 326, 653
  12. McPherson, 1994, BMJ, 309, 1003, 10.1136/bmj.309.6960.1003 · DOI

Cited by

See all 146

Metadata

Authors
Radice, D., & Redaelli, A.
Corresponding author
Redaelli, Alberto
Venue
PharmacoEconomics
Published
2003
Volume
21
Issue
6
Pages
383-396
ISSN
1170-7690 (ISSN-L)
OpenAlex
W2092610057
Cited by
146
References
53
Citations by year
2026: 1 · 2025: 7 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 2 · 2020: 8 · 2019: 4 · 2018: 1 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 2 · 2013: 9 · 2012: 6
FWCI
4.55
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
breast cancer, health-related quality of life, cancer treatment costs, economic burden of cancer, cytotoxic chemotherapy, endocrine therapy, radiotherapy, breast cancer incidence and mortality, cost-effectiveness, cancer screening, developing countries
MeSH terms
Adult, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Middle Aged, Quality of Life, Surveys and Questionnaires, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast Cancer Management: Quality-of-Life and Cost Considerations. https://app.cochat.ai/papers/10.2165/00019053-200321060-00003
The paper
Radice, D., & Redaelli, A. (2003). Breast Cancer Management: Quality-of-Life and Cost Considerations. PharmacoEconomics. https://doi.org/10.2165/00019053-200321060-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.